Marie Sébert

Délégation Paris 5 — France

Medicine · Health Sciences

26h-index2.8kcitations144works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(93), Histone Deacetylase Inhibitors Research(21), Myeloproliferative Neoplasms: Diagnosis and Treatment(18), Chronic Myeloid Leukemia Treatments(17), Hematopoietic Stem Cell Transplantation(13)

Publications144 total

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD
Blood·2025
Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo
Blood·2025Open Access
Characteristics and prognostic significance of myelodysplastic syndrome (MDS)-related features in vexas syndrome
Blood·2025Open Access
Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts
Blood·2025Open Access
Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
HemaSphere·2025Open Access
Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers
European Journal of Human Genetics·2025
Allogeneic hematopoietic stem cell transplantation in patients with germ line <i>DDX41</i> mutated myeloid malignancies
Blood Advances·2025Open Access
PLENARY SESSION 07: TREATMENT LOW RISK MDS (PART 2)
Leukemia Research·2025Open Access
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial
The Lancet Haematology·2025· 2 cited
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score
Blood·2025· 2 cited
Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine
Blood Advances·2025· 3 citedOpen Access
Prospective feasibility of a minimal <scp>BH3</scp> profiling assay in acute myeloid leukemia
Cytometry Part B Clinical Cytometry·2024· 4 citedOpen Access
Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study
Blood·2024· 7 citedOpen Access
Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine
Blood·2024
Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia
Haematologica·2024Open Access
Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule
Nature Cancer·2024· 23 citedOpen Access
Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen
Bone Marrow Transplantation·2024· 1 cited
Cutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms
Blood Advances·2024· 6 citedOpen Access
Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission
Blood Advances·2024· 2 citedOpen Access
Germline CHEK2 mutations in patients with myeloid neoplasms
Leukemia·2024· 4 cited
page 1 of 8Next →

Frequent Co-authors

Lionel Adès(36), Pierre Fenaux(36), Raphaël Itzykson(16), Emmanuelle Clappier(16), Emmanuel Raffoux(16), Thomas Cluzeau(12), Sylvie Chevret(12), Sylvain Thépot(11), Fatiha Chermat(10), Hervé Dombret(10), Étienne Lengliné(9), Nicolas Boissel(9), Jean Soulier(9), Pierre Péterlin(8), Aspasia Stamatoullas(8), Lin‐Pierre Zhao(7), A. Mékinian(7), Flore Sicre de Fontbrune(7), Christian Récher(7), Rathana Kim(7)